rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Study sponsor: AKARI Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-03-12Actual
Enrollment · participants9Actual
Source updated2025-04-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.